Novo Nordisk signs second licensing deal since capital-markets day
The agreement follows an investor meeting that drew a cool market reception, as the Danish drugmaker leans on external assets to refill its pipeline.
TR
By Tom Reyes · Markets Editor
Sep 29 05:45 ETSource: MarketWatch
The wire
- 01MarketWatch reports Novo Nordisk has struck its second licensing deal since a poorly received capital-markets day.
- 02Novo's dealmaking pace signals how the semaglutide maker plans to defend its position as incretin competition widens.
- 03Deal terms, the partner and the asset class were not detailed in the item; watch company filings for financial specifics.
From the source
Read at marketwatch.comNovo Nordisk strikes second licensing deal since frosty capital-markets day
